WO1997030178A2 - Diagnosing trinucleotide repeat diseases and genes involved therein - Google Patents
Diagnosing trinucleotide repeat diseases and genes involved therein Download PDFInfo
- Publication number
- WO1997030178A2 WO1997030178A2 PCT/FR1997/000297 FR9700297W WO9730178A2 WO 1997030178 A2 WO1997030178 A2 WO 1997030178A2 FR 9700297 W FR9700297 W FR 9700297W WO 9730178 A2 WO9730178 A2 WO 9730178A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequences
- sequence
- type
- clone
- name
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 title claims description 36
- 108700028369 Alleles Proteins 0.000 claims abstract description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 6
- 230000000295 complement effect Effects 0.000 claims abstract description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 description 39
- 239000002773 nucleotide Substances 0.000 description 39
- 125000003729 nucleotide group Chemical group 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 33
- 241000894006 Bacteria Species 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 9
- 230000035772 mutation Effects 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 208000012902 Nervous system disease Diseases 0.000 description 6
- 208000025966 Neurological disease Diseases 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 206010068871 Myotonic dystrophy Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 3
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- KINULKKPVJYRON-PVNXHVEDSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine;hydron;dichloride Chemical compound Cl.Cl.N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 KINULKKPVJYRON-PVNXHVEDSA-N 0.000 description 2
- 229920000155 polyglutamine Polymers 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010050389 Cerebral ataxia Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 241000223783 Glaucoma Species 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 101100182721 Mus musculus Ly6e gene Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to the detection of human genes comprising repetitive triplet sequences CAG or CTG, as well as the use of these genes in the diagnosis and the possible treatment of certain hereditary neurological diseases.
- CAG or CTG repeat triplet sequences constitutes a mutation involved in at least 6 human inherited neurological diseases (called “repeat triplet diseases”), in particular spinobulbar muscle atrophy (SBMA), myotonic dystrophy (MD), cerebro-spinal ataxia (SCAS) 1 and 3, den-ato-rubro-pallydoluysiane atrophy (DRPLA) and Huntington's disease (HD) (1).
- SBMA spinobulbar muscle atrophy
- MD myotonic dystrophy
- SCAS cerebro-spinal ataxia
- DRPLA den-ato-rubro-pallydoluysiane atrophy
- HD Huntington's disease
- CAG / CTG also called dynamic mutation
- CAG / CTG repeats can occur in the non-coding (MD) or coding (eg SBMA and HD) regions of the transcripts. These transcripts are sometimes expressed in tissues other than the brain and when translated result in larger gene products carrying an abnormally elongated polyglutamine domain (2 to 4).
- the foregoing demonstrates the considerable importance of repeated triplet diseases and the importance of their diagnosis and treatment.
- the present invention is based on a systematic study of CAG / CTG repeats (which will be designated hereinafter by "[CAG] n", n being the number of repeats of the triplet), this study having been carried out with human cDNA libraries , these having undergone a first general screening, then the selected sequences having been selected on the basis of a certain number of criteria making it possible to ensure that the sequences in question belonged to new human genes and could, with great probability, to be implicated in diseases with repeated triplet. Finally, the selected sequences were the subject of a more complete study intended to allow their localization.
- two sets of cDNAs from human brains were studied to analyze the presence of CAG repeats using hybridization of oligonucleotides on high density membranes.
- the two libraries were obtained from mRNAs using the oligo-dT primer, one of the libraries being made up of fetal brain (FB) cDNA clones and the other library being made up of clones of Normalized newborn brain cDNA (NIB).
- FB fetal brain
- NBI Normalized newborn brain cDNA
- human ESTs in databases have been analyzed for the presence of repeated triplets in cDNAs from human tissues other than the brain.
- the present invention is based on the demonstration of certain sequences capable of being implicated in repeated triplet diseases obtained under hybridization conditions making it possible to select cDNAs which contain a number of sequences [CAG] greater than 9, which are more likely to be polymorphic in a normal population. 0
- the present invention relates to a transcribed DNA sequence rich in repeated triplet CAG or CTG corresponding to sequences A to I of the table, as well as their normal and mutated alleles and the complementary sequences.
- normal alleles is meant the alleles as they have been isolated or as they can be isolated from samples from normal individuals, the “mutated alleles” being the alleles of the genes carrying your sequences [CAG] n abnormally repeated.
- sequences in question are for the first time identified as being part of a gene which may present a dynamic mutation, said genes not having , moreover, in themselves never been described.
- sequences are identified in the table and can, if necessary, be re-isolated using the following primers: SEQ. ID 1 to 18, primers 1 to 1 8 corresponding, in pairs, to the sequences A to 1 mentioned above.
- sequences thus highlighted can, first of all, be used within the framework of the diagnosis, and more exactly of a prognosis. Indeed, like a large number of diseases having a genetic support, the demonstration of the presence of a sequence presenting an abnormal number of repetitions of triplet [CAGjn cannot in itself ensure the occurrence of the disease, but must be interpreted according to a set of other information to allow either a very early diagnosis or possibly specific surveillance, especially in families at risk.
- This diagnosis can be made by comparing the DNA sequence according to the patient's invention with a normal sequence to detect the presence of additional nucleotide repeats.
- the present invention relates to a method for demonstrating the risks of the appearance of a trinucleotide recurrent disease in a patient, characterized in that the DNA sequence according to claim 1 of said patient is compared to a normal sequence to detect the presence of additional trinucleotide repeats.
- a method for demonstrating the risks of the appearance of a trinucleotide recurrent disease in a patient characterized in that the DNA sequence according to claim 1 of said patient is compared to a normal sequence to detect the presence of additional trinucleotide repeats.
- the most effective methods consist in carrying out an amplification operation, before highlighting the differences, by any suitable method, in particular the so-called "PCR" method, even if other methods can be used.
- primers which can be used in the context of the methods according to the invention, mention should be made of the primers of SEQ . ID 1 to 1 S which constitute two by two of the pairs of primers for each of the sequences object of the invention.
- the sequences according to the present invention are amplified and it is then possible, by comparison with a normal and / or standard sample, to demonstrate the presence of the supernumerary triplets and therefore the possibility of occurrence of a disease linked to this type of dynamic mutation. It is also interesting to note that these dynamically mutated diseases are known to be all the more severe and to occur the sooner the greater the number of repetitions.
- the diagnostic method can allow not only a good prognosis for the onset of the disease, but also to assess the time when this disease will occur and / or its possible severity.
- the present invention also relates to genes and their alleles which carry, at least in part, these sequences, said genes being, of course, directly involved in the onset of the disease.
- the corresponding genes can be expressed in cells by known means in order to produce the corresponding proteins.
- these proteins being involved in the disease, it is desired to reduce their quantity, either by blocking their expression by appropriate methods at the level of genes or regulatory elements, or by fixing or inactivating them, for example using receptor proteins acting as decoys. Again, these receptor or inactivated proteins can be generated in situ by expression of the corresponding DNA sequences.
- proteins with abnormally large polyglutamic domains us av have abnormal aggregation properties, both with each other and with other proteins (7, 8)
- the aggregates thus created are probably involved in the genesis of triplet repeat diseases, this is why it is also possible to provide a therapy in which the therapeutic agents would prevent aggregation, either by blocking the molecule as described above, or by attaching to the molecule to prevent approximation with other proteins.
- sequences according to the present invention can be obtained thanks to the information appearing in the table and to the references which are given therein and by using the primer sequences which are described in the attached sequence identifiers.
- the two libraries used are: a first library (5) containing 60,000 non-standard cDNAs of human fetal brain (FB clones) (Laboratory of Dr. Hans Lehrach, Max Plank Institute for Molecular Genetics, Berlin, Germany) subclones in the vector p-SPORT- 1 (Life Technologies, Inc., Gaithesburg,
- the second library contains 40,128 normalized cDNAs for newborn brains (NIB clones) subcloned into a laf id (6) vector and which is part of the resources of the I MAGE consortium (Lawrence Livermore Lab ., Livermore, CA,) and the EST Merck WU program
- clone 2.1 16 which is located on chromosome 3pl4 and possibly involved in ADCA II, the other highly polymorphic sequences [CAGjn previously described do not correspond to any known locus for hereditary neurological diseases.
- This clone 2.1 16 was found to correspond to a transcript of 2227 base pairs highly expressed in skeletal muscles and weakly expressed in the brain according to the Northern Blot analysis. The repetition of the polymorphic CAG sequences is localized at the level of the 3 'untranslated region of the mRNA.
- the RNA corresponding to clone 2.1 16 codes for a putative protein of 137 amino acids (nt 127 to 538) having no homology with proteins known in Genbank.
- the complete sequence of the transcript of clone 2. 1 16 is represented by SEQ D 19.
- IS sequence homologies with the IS in Genbank: nu mero access ESTs in Genbank
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
DIAGNOSTIC DES MALADIES Λ REPETITION TRINUCLEOTIDIQUE ET GENES IMPLIQUES DANS CES MALADIESDIAGNOSIS OF TRINUCLEOTIDE REPETITIVE DISEASES AND GENES INVOLVED IN SUCH DISEASES
La présente invention concerne la mise en évidence de gènes humains comportant des séquences à triplet répété CAG ou CTG, ainsi que l'utilisation de ces gènes dans le diagnostic et l'éventuel traitement de certaines maladies neurologiques héréditaires.The present invention relates to the detection of human genes comprising repetitive triplet sequences CAG or CTG, as well as the use of these genes in the diagnosis and the possible treatment of certain hereditary neurological diseases.
L'expansion de séquences à triplet répété CAG ou CTG hautement polymorphiques et instables constitue une mutation impliquée dans au moins 6 maladies neurologiques héréditaires humaines (appelées "maladies à triplet répété ") , notamment l'atrophie musculaire spinobulbaire (SBMA), la dystrophie myotonique (MD), l'ataxie cérébro¬ spinale (SCAS) 1 et 3, l'atrophie den-ato-rubro-pallydoluysiane (DRPLA) et la maladie d'Huntington (HD) ( 1 ).The expansion of highly polymorphic and unstable CAG or CTG repeat triplet sequences constitutes a mutation involved in at least 6 human inherited neurological diseases (called "repeat triplet diseases"), in particular spinobulbar muscle atrophy (SBMA), myotonic dystrophy (MD), cerebro-spinal ataxia (SCAS) 1 and 3, den-ato-rubro-pallydoluysiane atrophy (DRPLA) and Huntington's disease (HD) (1).
L'expansion des CAG/CTG (appelée également mutation dynamique) dans chacune de ces maladies est associée à un phénomène d'anticipation, la taille des répétitions étant souvent corrélée de façon inverse avec l'âge de la survenue et/ou de la sévérité des symptômes.The expansion of CAG / CTG (also called dynamic mutation) in each of these diseases is associated with a phenomenon of anticipation, the size of the repetitions often being inversely correlated with the age of onset and / or severity symptoms.
L'expansion des répétitions CAG/CTG peut apparaître dans les régions non codantes (MD) ou codantes (par exemple SBMA et HD) des transcrits. Ces transcrits sont parfois exprimés dans les tissus autres que le cerveau et lorsqu'ils sont traduits conduisent à des produits de gènes plus grands portant un domaine polyglutamine anormalement allonge (2 à 4).The expansion of CAG / CTG repeats can occur in the non-coding (MD) or coding (eg SBMA and HD) regions of the transcripts. These transcripts are sometimes expressed in tissues other than the brain and when translated result in larger gene products carrying an abnormally elongated polyglutamine domain (2 to 4).
La mise en évidence d'expansion CAG/CTG dans l'ADN génomique de patients et/ou l'anticipation dans les familles à risque a suggéré que les mutations dynamiques sont impliquées dans SCA 2, SCA 4 et SCA 5, l'ataxie cérébrale dominante autosomale (ADCA de type 2) et la forme familiale du désordre affectif bipolaire ( BPAD) ou la schizophrénie. L'autisme et la démence familiale qui montrent des variabilités dans l'âge de la survenue ou dans la sévérité des symptômes pourraient également être causés par des mutations dynamiques.Evidence of CAG / CTG expansion in patient genomic DNA and / or anticipation in families at risk suggested that dynamic mutations are involved in SCA 2, SCA 4 and SCA 5, cerebral ataxia dominant autosomal (ADCA type 2) and the familial form of bipolar affective disorder (BPAD) or schizophrenia. Autism and familial dementia, which show variability in the age of onset or in the severity of symptoms, could also be caused by dynamic mutations.
Un assez grand nombre de maladies pourraient également avoir pour origine ou impliquer des mutations dynamiques :A fairly large number of diseases could also originate or involve dynamic mutations:
- la maladie de Parkinson,- Parkinson's disease,
- les paraplégies spastiques, - les ataxies cérébrospinale non répertoriées précédemment,- spastic paraplegias, - cerebrospinal ataxias not previously listed,
- les cataractes zonulaires, /30178- zonular cataracts, / 30178
- les tremblements incontrôlables,- uncontrollable tremors,
- les neuropathies amyloïdes familiales,- familial amyloid neuropathies,
- les arthrites granulomateuses familiales (maladie de Blau),- family granulomatous arthritis (Blau's disease),
- les microsomies hémifaciales, - certaines anémies et glaucomes,- hemifacial microsomies, - certain anemias and glaucomas,
- les désordres obsessionnels.- obsessive-compulsive disorder.
Ce q ui précède démon tre l 'importance considérable des maladies à triplet répété et l'importance de leur diagnostic et de leur traitement. La présente invention repose sur une étude systématique des répétitions CAG/CTG (qui seront ci-après désignées par "[CAG]n", n étant le nombre de répétitions du triplet), cette étude ayant été réalisée avec des banques d'ADNc humains, celles-ci ayant subi un premier criblage général, puis les séquences retenues ayant été sélectionnées sur la base d'un certain nombre de critères permettant de s'assurer que les séquences en cause appartenaient à de nouveaux gènes humains et pouvaient, avec une grande probabilité, être impliquées dans des maladies à triplet répété. Enfin, les séquences sélectionnées ont fait l'objet d'une étude plus complète destinée à permettre leur localisation. Dans le cadre de la présente invention, deux ensembles d'ADNc provenant de cerveaux humains ont été étudiés pour analyser la présence de répétitions CAG en utilisant l'hybridation d 'oligonucleotides su r des membranes à haute densité. Les deux librairies ont été obtenues à partir de ARNms à l'aide d'amorce oligo-dT, l'une des librairies étant constituée de clones d 'ADNc de cerveau foetal (FB) et l'autre librairie étant constituée de clones d'ADNc normalisés de cerveau de nouveau-né (NIB).The foregoing demonstrates the considerable importance of repeated triplet diseases and the importance of their diagnosis and treatment. The present invention is based on a systematic study of CAG / CTG repeats (which will be designated hereinafter by "[CAG] n", n being the number of repeats of the triplet), this study having been carried out with human cDNA libraries , these having undergone a first general screening, then the selected sequences having been selected on the basis of a certain number of criteria making it possible to ensure that the sequences in question belonged to new human genes and could, with great probability, to be implicated in diseases with repeated triplet. Finally, the selected sequences were the subject of a more complete study intended to allow their localization. In the context of the present invention, two sets of cDNAs from human brains were studied to analyze the presence of CAG repeats using hybridization of oligonucleotides on high density membranes. The two libraries were obtained from mRNAs using the oligo-dT primer, one of the libraries being made up of fetal brain (FB) cDNA clones and the other library being made up of clones of Normalized newborn brain cDNA (NIB).
De plus, les ESTs humains dans les banques de données ont été analysés pour détecter la présence de triplets répétés dans les ADNc de tissus humains autres que le cerveau. De façon générale, la présente invention repose sur la mise en évidence de certaines séquences susceptibles d'être impliquées dans les maladies à triplet répété obtenues dans des conditions d'hybridation permettant de sélectionner des ADNc qui contiennen t un nombre de séq uences [CAG] supérieur à 9, lesquelles sont plus susceptibles d'être polymorphes dans une population normale. 0In addition, human ESTs in databases have been analyzed for the presence of repeated triplets in cDNAs from human tissues other than the brain. In general, the present invention is based on the demonstration of certain sequences capable of being implicated in repeated triplet diseases obtained under hybridization conditions making it possible to select cDNAs which contain a number of sequences [CAG] greater than 9, which are more likely to be polymorphic in a normal population. 0
Les conditions complètes d'analyse et de sélection de ces différentes séquences ne seront pas détaillées ci-après, seuls seront fournis les éléments permettant de les localiser et de les rcisolcr grâce, notamment, aux amorces PCR qui seront décrites ci-après. Plus particulièrement, la présen te invention concerne une séquence d'ADN transcrit riche en triplet répété CAG ou CTG correspondant aux séquences A à I du tableau, ainsi que leurs alleles normaux et mutés et les séquences complémentaires.The complete conditions of analysis and selection of these different sequences will not be detailed below, only the elements making it possible to locate and to isolate them will be provided, in particular, thanks to the PCR primers which will be described below. More particularly, the present invention relates to a transcribed DNA sequence rich in repeated triplet CAG or CTG corresponding to sequences A to I of the table, as well as their normal and mutated alleles and the complementary sequences.
Par "alleles normaux" on entend désigner les alleles tels qu 'ils ont été isolés ou tels qu'il peuvent être isolés de prélèvements d'individus normaux, les "alleles mutés" étant les alleles des gènes portant tes séquences [CAG]n anormalement répétées.By "normal alleles" is meant the alleles as they have been isolated or as they can be isolated from samples from normal individuals, the "mutated alleles" being the alleles of the genes carrying your sequences [CAG] n abnormally repeated.
Il est important de noter que, bien que certaines de ces séquences soient, totalement ou en partie, publiques, les séquences en cause sont pour la première fois identifiées comme faisant partie d'un gène pouvant présenter une mutation dynamique, lesdits gènes n'ayant, par ailleurs, en eux-mêmes jamais été décrits.It is important to note that, although some of these sequences are, in whole or in part, public, the sequences in question are for the first time identified as being part of a gene which may present a dynamic mutation, said genes not having , moreover, in themselves never been described.
Les séquences ainsi mises en évidence présentent, notamment pour sept d 'entre elles, un pourcentage d'hétérozygotie (pourcentage HTZ) suffisamment important pour être impliquées très directement dans des maladies à triplet répété. Les séquences E et 1 qui présentent un très faible taux d'hétérozygotie (HTZ : 0,05) sont moins susceptibles d'être impliquées dans de telles maladies.The sequences thus highlighted present, in particular for seven of them, a percentage of heterozygosity (percentage HTZ) sufficiently large to be involved very directly in diseases with repeated triplets. Sequences E and 1 which have a very low rate of heterozygosity (HTZ: 0.05) are less likely to be involved in such diseases.
Bien entendu, comme cela est mentionné précédemment, ces séquences sont identifiées dans le tableau et pourront, si besoin est, être réisolées en utilisant les amorces suivantes : SEQ. ID 1 à 18, les amorces 1 à 1 8 correspondant, par paire, aux séquences A à 1 mentionnées précédemment.Of course, as mentioned previously, these sequences are identified in the table and can, if necessary, be re-isolated using the following primers: SEQ. ID 1 to 18, primers 1 to 1 8 corresponding, in pairs, to the sequences A to 1 mentioned above.
Les séquences ainsi mises en évidence peuvent, tout d'abord, être utilisées dans le cadre du diagnostic, et plus exactement d'un pronostic. En effet, comme un grand nombre de maladies ayant un support génétique, la mise en évidence de la présence d'une séquence présentant un nombre de répétitions anormal de triplet [CAGjn ne peut en elle-même assurer de la survenue de la maladie, mais doit être interprétée en fonction d'un ensemble d'autres informations pour permettre, soit un diagnostic très précoce, soit éventuellement une surveillance spécifique, surtout dans les familles à risque. Ce diagnostic peut être effectué en comparan t la séquence d'ADN selon l'invention du patient avec une séquence normale pour détecter la présence de répétitions tπnucléotidiqucs supplémentaires.The sequences thus highlighted can, first of all, be used within the framework of the diagnosis, and more exactly of a prognosis. Indeed, like a large number of diseases having a genetic support, the demonstration of the presence of a sequence presenting an abnormal number of repetitions of triplet [CAGjn cannot in itself ensure the occurrence of the disease, but must be interpreted according to a set of other information to allow either a very early diagnosis or possibly specific surveillance, especially in families at risk. This diagnosis can be made by comparing the DNA sequence according to the patient's invention with a normal sequence to detect the presence of additional nucleotide repeats.
Plus partic ulièrement, la présente invention concerne un procédé de mise en évidence des risques d 'apparition d'une maladie a répétition trinucléotidique chez un patient, caractérisé en ce qu 'on compare la séquence d'ADN selon la revendication 1 dudit patient à une séquence normale pour détecter la présence de répétitions trinucléotidiq ues supplémentaires. Bien en tendu, il existe un grand nombre de méthodes qui permettent la mise en évidence de triplets surnuméraires par rapport à des séquences normales, par exemple il est possible de mettre en évidence des différences de poids moléculaires en utilisant des gels et une méthode de type RFLP. Mais, les méthodes les plus efficaces consistent à pratiquer préalablement à la mise en évidence des différences une opération d'amplification, par toute méthode appropriée, notamment la méthode dite "PCR", même si d'autres méthodes sont utilisables.More particularly, the present invention relates to a method for demonstrating the risks of the appearance of a trinucleotide recurrent disease in a patient, characterized in that the DNA sequence according to claim 1 of said patient is compared to a normal sequence to detect the presence of additional trinucleotide repeats. Although in tension, there are a large number of methods which allow the highlighting of supernumerary triplets compared to normal sequences, for example it is possible to highlight differences in molecular weights using gels and a type method RFLP. However, the most effective methods consist in carrying out an amplification operation, before highlighting the differences, by any suitable method, in particular the so-called "PCR" method, even if other methods can be used.
Il n'est pas nécessaire ici de décrire en détail la méthode PCR, celle-ci permet d'amplifier de façon considérable une séquence spécifique comprise entre deux séquences appelées "amorces".It is not necessary here to describe in detail the PCR method, it makes it possible to considerably amplify a specific sequence comprised between two sequences called "primers".
Parmi les amorces utilisables dans le cadre des procédés selon l'invention, il faut citer les amorces des SEQ. ID 1 à 1 S qui consti tuent deux par deux des paires d'amorces pour chacune des séquences objet de l'inven tion. En utilisant les amorces décrites précédemment, on amplifie les séquences selon la présente invention et i l est alors possible, par comparaison avec un échantillon normal et/ou étalon, de mettre en évidence la présence des triplets surnuméraires et donc la possibilité de survenue d'une maladie liée à ce type de mutation dynamique. II est également intéressant de noter que ces maladies à mutation dynamique sont connues pour être d'autant plus sévères et survenir d'autant plus tôt qu'est important le nombre de répétitions. Dans ces conditions, la méthode diagnostic peut permettre, non seulement un bon pronostic de la survenue de la maladie, mais également d'évaluer le moment où cette maladie surviendra et/ou son éventuelle sévérité. La présente invention concerne également les gènes et leurs alleles qui portent, au moins en parties, ces séquences, lesdits gènes étant, bien entendu, impliqués directement dans la survenue de la maladieAmong the primers which can be used in the context of the methods according to the invention, mention should be made of the primers of SEQ . ID 1 to 1 S which constitute two by two of the pairs of primers for each of the sequences object of the invention. Using the primers described above, the sequences according to the present invention are amplified and it is then possible, by comparison with a normal and / or standard sample, to demonstrate the presence of the supernumerary triplets and therefore the possibility of occurrence of a disease linked to this type of dynamic mutation. It is also interesting to note that these dynamically mutated diseases are known to be all the more severe and to occur the sooner the greater the number of repetitions. Under these conditions, the diagnostic method can allow not only a good prognosis for the onset of the disease, but also to assess the time when this disease will occur and / or its possible severity. The present invention also relates to genes and their alleles which carry, at least in part, these sequences, said genes being, of course, directly involved in the onset of the disease.
Les gènes correspondant pourront être exprimés dans des cellules par des moyens connus afin de produire les protéines correspondantes.The corresponding genes can be expressed in cells by known means in order to produce the corresponding proteins.
Il est possible d'envisager l'utilisation desdues protéines dans certains kits de diagnostic par exemple.It is possible to consider the use of proteins in certain diagnostic kits for example.
De façon générale, ces protéines étant impliq uées dans la maladie, on souhaitera en diminuer la quantité, soit en bloquant leur expression par des méthodes appropriées au niveau des gènes ou des éléments de régulation, soit en les fixant ou en les inactivant, par exemple en utilisant des protéines réceptrices jouant le rôle de leurres. Là encore, ces protéines réceptrices ou inactivées pourront être générées m situ par expression des séquences d'ADN correspondantesIn general, these proteins being involved in the disease, it is desired to reduce their quantity, either by blocking their expression by appropriate methods at the level of genes or regulatory elements, or by fixing or inactivating them, for example using receptor proteins acting as decoys. Again, these receptor or inactivated proteins can be generated in situ by expression of the corresponding DNA sequences.
Il est également possible de prévoir la réalisation d 'anticorps monoclonaux correspondant à ces protéines afin d 'envisager le blocage desdites protéines lorsque cela est souhaité, l 'ensemble de ces opérations pouvant être réalisé directement in vivo par exemple, en utilisant des techniques de thérapie génique, en particulier en utilisant des vecteurs qui porteront les séquences d'expression des gènes.It is also possible to provide for the production of monoclonal antibodies corresponding to these proteins in order to envisage blocking said proteins when desired, all of these operations can be performed directly in vivo for example, using therapy techniques. gene, in particular using vectors that will carry the gene expression sequences.
On a mis en évidence le fait que les protéines présentant des domaines polyglutam es anormalement étend us av aient des propriétés d'aggrégation anormales, tant entre elles, qu'avec d'autres protéines (7, 8 ) Les aggrégats ainsi créés sont probablement impliques dans la genèse des maladies à triplet répète, c'est pourquoi il est également possible de prévoir une thérapie dans laquelle les agents thérapeutiques viendraient empêcher l'aggrégation, soit en bloquant la molécule comme décrit précédemment, soit en se fixant à la molécule pour empêcher le rapprochement avec d'autres protéines.It has been demonstrated that proteins with abnormally large polyglutamic domains us av have abnormal aggregation properties, both with each other and with other proteins (7, 8) The aggregates thus created are probably involved in the genesis of triplet repeat diseases, this is why it is also possible to provide a therapy in which the therapeutic agents would prevent aggregation, either by blocking the molecule as described above, or by attaching to the molecule to prevent approximation with other proteins.
On peut, dans le cadre de la thérapie, prévoir d'utiliser des variants complets ou délétés de ces protéines, normales ou non (quant au domaine [CAGjn).One can, within the framework of the therapy, plan to use complete or deleted variants of these proteins, normal or not (as for the domain [CAGjn).
Les séquences selon la présente invention peuvent être obtenues grâce aux informations figurant au tableau et aux références qui y sont données et en utilisant les séquences d'amorce qui sont décrues dans les identificateurs de séquence ci-joints. Les deux librairies utilisées sont : une première librairie (5 ) contenant 60 000 ADNc non normalisés de cerveau foetal humain (clones FB) (Laboratoire du Dr. Hans Lehrach, Max Plank Institute for Molecular Genetics, Berlin, Allemagne) sous- clones dans le vecteur p-SPORT- 1 (Life Technologies, Inc., Gaithesburg,The sequences according to the present invention can be obtained thanks to the information appearing in the table and to the references which are given therein and by using the primer sequences which are described in the attached sequence identifiers. The two libraries used are: a first library (5) containing 60,000 non-standard cDNAs of human fetal brain (FB clones) (Laboratory of Dr. Hans Lehrach, Max Plank Institute for Molecular Genetics, Berlin, Germany) subclones in the vector p-SPORT- 1 (Life Technologies, Inc., Gaithesburg,
MA, USA), et la seconde librairie contient 40 128 ADNc normalisés de cerveau de nouveau-né (clones NIB) sous-clonés dans un vecteur laf id (6) et qui est une partie des ressources du consortium I MAGE ( Lawrence Livermore Lab., Livermore, CA, ) et du programme EST Merck WUMA, USA), and the second library contains 40,128 normalized cDNAs for newborn brains (NIB clones) subcloned into a laf id (6) vector and which is part of the resources of the I MAGE consortium (Lawrence Livermore Lab ., Livermore, CA,) and the EST Merck WU program
(Washington University, St-Louis, LO, USA) .(Washington University, St-Louis, LO, USA).
D'autre part, un certain nombre d'autres informations ont été recueillies en utilisant Genbank Database (NCBl Bethesda, MA, USA).On the other hand, a number of other information was collected using the Genbank Database (NCBl Bethesda, MA, USA).
Les méthodes de sélection et d'analyse qui ont été mises en oeu\ re ne font pas en elles-mêmes partie de la présente invention puisque l'invention a essentiellement pour objet les séquences ainsi obtenues et leur utilisation, notamment, dans des méthodes de diagnostic ou des méthodes de traitement thérapeutique.The methods of selection and analysis which have been implemented do not in themselves form part of the present invention since the invention essentially relates to the sequences thus obtained and their use, in particular, in methods of diagnostic or therapeutic treatment methods.
Dans la présente analyse, on a retenu, non seulemen t les séquences polymorphiques [CAGjn parfaites, mais également les séquencesIn the present analysis, we have retained, not only the perfect polymorphic sequences [CAGjn, but also the sequences
[CAGjn complexes, c'est-à-dire celles qui sont ponctuées par des insertions de triplets ; en effet cette présence de triplets insérés s'observe notamment dans le cas de SCA 1 , alors que tel n'est pas le cas pour SBMA, MD et I ID.[CAGjn complexes, ie those which are punctuated by insertions of triplets; indeed, this presence of inserted triples is observed in particular in the case of SCA 1, while such is not the case for SBMA, MD and I ID.
L'étude présen te a montré que le polymorph isme [CAG j n apparaît lorsque la séquence (CAGjn contient plus de 9 copies CAG ( n > 9) ; c'est pourquoi, dans les sélections effectuées, les conditions de stringencc sont assez élevées, ce qui a permis de sélectionner rapidement un grand nombre de séquences [CAGj n dans lesquelles n est supérieur à 9. D'ailleurs, les séquences [CAGjn dans lesquelles n est inférieur à 10 et qui ont pu être testées dans le cad re de la présente inven tion on t montré u n polymorphisme nul.The present study showed that the polymorphism [CAG jn appears when the sequence (CAGjn contains more than 9 CAG copies (n> 9); this is why, in the selections made, the conditions of stringencc are quite high, which made it possible to quickly select a large number of sequences [CAGj n in which n is greater than 9. Moreover, the sequences [CAGjn in which n is less than 10 and which could be tested within the framework of the present invention we have shown a null polymorphism.
Par contre, il n'est pas possible de relever u ne corrélation directe entre la longueur des séquences [CAGj n et le degré de polymorphisme. 97/30178On the other hand, it is not possible to detect a direct correlation between the length of the sequences [CAGj n and the degree of polymorphism. 97/30178
77
D'autre part, les nouveaux clones sélectionnes a partir de librairies NIB sont distincts de ceux sélectionnés dans le groupe FB Ceci est en accord avec le fait que le cerveau humain exprime un grand nombre de gènes distincts à des stades de développement différents Enfin, des présentes observations il ressort que des séquencesOn the other hand, the new clones selected from NIB libraries are distinct from those selected from the FB group. This is in agreement with the fact that the human brain expresses a large number of distinct genes at different stages of development. present observations it appears that sequences
[CAGjn supérieures à 9 sont rares ( 1 pour 2 200 ) 1 pour 3 000) dans les ADNc humains représentatifs des régions 3' des ARNm.[CAGjn greater than 9 are rare (1 in 2,200) 1 in 3,000) in human cDNAs representative of the 3 ′ regions of the mRNAs.
Bien que dans l'état actuel de la présente invention , les séquences qui constituent l'objet de l'invention n'aient pas été reliées directement à des affections neurologiques héréditaires, la présence d'extensions anormales CAG peut être reliée avec le risque de survenue d'une maladie neurologique, en particulier lorsqu 'il y a une composante, familiale.Although in the present state of the present invention, the sequences which constitute the subject of the invention have not been directly linked to hereditary neurological disorders, the presence of abnormal CAG extensions may be linked with the risk of occurrence of a neurological disease, especially when there is a family component.
Sauf pour le clone 2.1 16 qui est localisé sur le chromosome 3pl4 et peut-être impliqué dans ADCA II, les autres séquences hautement polymorphiques [CAGjn décrues précédemment ne correspondent à aucun locus connu pour des maladies neurologiques héréditaires. Il a été trouvé que ce clone 2.1 16 correspondait à un transcrit de 2 227 paires de base hautement exprimé dans les muscles squelettiques et faiblement exprimé dans le cerveau d'après l'analyse Northern Blot. La répétition des séquences CAG polymorphiques est localisée au niveau de la région 3 ' non traduite de l'ARNm. L'ARN correspondant au clone 2.1 16 code pour une protéine putative de 137 acides aminés (nt 127 à 538) ne présentant aucu ne homologie avec des protéines connues dans Genbank La séquence complète du transcrit du clone 2. 1 16 est représentée par SEQ D 19.Except for clone 2.1 16 which is located on chromosome 3pl4 and possibly involved in ADCA II, the other highly polymorphic sequences [CAGjn previously described do not correspond to any known locus for hereditary neurological diseases. This clone 2.1 16 was found to correspond to a transcript of 2227 base pairs highly expressed in skeletal muscles and weakly expressed in the brain according to the Northern Blot analysis. The repetition of the polymorphic CAG sequences is localized at the level of the 3 'untranslated region of the mRNA. The RNA corresponding to clone 2.1 16 codes for a putative protein of 137 amino acids (nt 127 to 538) having no homology with proteins known in Genbank. The complete sequence of the transcript of clone 2. 1 16 is represented by SEQ D 19.
Néanmoins, il existe un assez grand nombre de maladies neurologiques qui actuellement n'ont pas été localisées et trouveront probablement à être reliées avec les séquences selon la présente invention Parmi les éléments additionnels qui ont été pris en compte pour étudier la pertinence des séquences retenues figure l'existence éventuelle d'un cadre de lecture ouvert (ORF) dans lequel les séquences [CAGjn codent pour une extension polyglutamine.Nevertheless, there are a fairly large number of neurological diseases which currently have not been localized and will probably find a link with the sequences according to the present invention. Among the additional elements which have been taken into account in order to study the relevance of the sequences retained. the possible existence of an open reading frame (ORF) in which the sequences [CAGjn code for a polyglutamine extension.
Enfin, la présente étude suggère que la fréquence d u polymorphisme [CAGjn est un événement rare dans les ADNc humains représentatifs des régions 3' des ARNm. TABLEAUFinally, the present study suggests that the frequency of polymorphism [CAGjn is a rare event in human cDNAs representative of the 3 'regions of mRNAs. BOARD
ICAGln polymoφhiques : caractéristiquesPolymorphic ICAGln: characteristics
Clone : Nom du clone d'ADNc (nom CEPH) - Mode de sélection - Répétition 5"-3'Clone: Name of the cDNA clone (CEPH name) - Selection mode - Repeat 5 " -3 '
EST : Homologies de séquence avec les EST dans Genbank : nu méro d'accès des ESTs dans GenbankIS: sequence homologies with the IS in Genbank: nu mero access ESTs in Genbank
YAC(s) posltifis) : (Noms du CEPH) pour la séquence testéeYAC (s) posltifis): (Names of CEPH) for the sequence tested
STS+/STS- : YAC posi if /négatif pour d'au tres STS(s) Alu target : YAC non utilisé comme sonde Alu Alu probe : YAC utilisé comme sonde AluSTS + / STS-: YAC positive / negative for other STS (s) Alu target: YAC not used as Alu probe Alu probe: YAC used as Alu probe
Localisation : Localisation de la séquence testée dans les chromosomes humains (déduction d'après les YACs positifs) Location: Location of the sequence tested in human chromosomes (net of after positive YAC)
LISTE DE SEQUENCESLIST OF SEQUENCES
( 1 ) INFORMATIONS GENERALES (i) DEPOSANT : (A) NOM : FONDATION JEAN DAUSSET - CENTRE D'ETUDE DU(1) GENERAL INFORMATION (i) DEPOSITOR: (A) NAME: JEAN DAUSSET FOUNDATION - STUDY CENTER
POLYMORPHISME HUMAIN (CEPH).HUMAN POLYMORPHISM (CEPH).
(B) RUE : 27 Rue Juliette Dodu(B) STREET: 27 Rue Juliette Dodu
(C) VILLE : PARIS(C) CITY: PARIS
(D) PAYS : FRANCE (E) CODE POSTAL : 75010(D) COUNTRY: FRANCE (E) POSTAL CODE: 75010
(ii) TITRE DE L'INVENTION : DIAGNOSTIC DES MALADIES A REPETITION(ii) TITLE OF THE INVENTION: DIAGNOSIS OF REPETITIVE DISEASES
TRINUCLEOTIDIQUE ET GENES IMPLIQUES DANS CES MALADIESTRINUCLEOTIDE AND GENES INVOLVED IN THESE DISEASES
(iii) NOMBRE DE SEQUENCES : 18(iii) NUMBER OF SEQUENCES: 18
(iv) FORME DECHIFFRABLE PAR ORDINATEUR :(iv) COMPUTER-DETACHABLE FORM:
(A) TYPE DE SUPPORT : Floppy disk (B) ORDINATEUR : MACINTOSH APPLE(A) TYPE OF MEDIUM: Floppy disk (B) COMPUTER: MACINTOSH APPLE
(C) SYSTEM E D'EXPLOITATION : MAC-OS SYSTEME 7(C) OPERATING SYSTEM E: MAC-OS SYSTEM 7
( D) LOGICIEL : WORDPERFECT(D) SOFTWARE: WORDPERFECT
(v) DONNEES DE LA DEMANDE ACTUELLE : NUMERO DE LA DEMANDE :(v) CURRENT REQUEST DATA: REQUEST NUMBER:
(2) INFORMATIONS POUR LA SEQID NO 1 :(2) INFORMATION FOR SEQID NO 1:
. (i) CARACTERISTIQUES DE LA SEQUENCE: (A) LONGUEUR : 15 nucléotides. (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 15 nucleotides
(B) TYPE : nucléotide(B) TYPE: nucleotide
(C) NOMBRE DE BRIN : simple(C) NUMBER OF STRANDS: single
(D) CONFIGURATION : linéaire(D) CONFIGURATION: linear
(ii) TYPE DE MOLECULE : ADNc (iii) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEU R DE LA MOLECULE :(ii) TYPE OF MOLECULE: cDNA (iii) CHARACTERISTICS OF THE CARRIER CELL CLONE OF THE MOLECULE:
(A) TYPE DE CELLULE : bactérie(A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT : 2.1 16 (C) ORIGINE : Max Plank Institute for Molecular Genctics(B) NAME OF THE cDNA CLONE IN THE APPLICANT: 2.1 16 (C) ORIGIN: Max Plank Institute for Molecular Genctics
Laboratory of Dr Hans Lehrach, Berlin, Allemagne. (D) NOM DU CLONE DANS LA BANQUE D'ORIGINE :ICRFp507E07266Laboratory of Dr Hans Lehrach, Berlin, Germany. (D) NAME OF THE CLONE IN THE BANK OF ORIGIN: ICRFp507E07266
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
CCAGCCTCAG GTAGC 15CCAGCCTCAG GTAGC 15
(2) INFORMATIONS POUR LA SEQID NO 2 :(2) INFORMATION FOR SEQID NO 2:
(i) CARACTERISTIQUES DE LA SEQUENCE:(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LONGUEUR : 22 nucléotides(A) LENGTH: 22 nucleotides
(B) TYPE : nucléotide(B) TYPE: nucleotide
(C) NOMBRE DE BRIN : simple(C) NUMBER OF STRANDS: single
(D) CONFIGURATION : linéaire(D) CONFIGURATION: linear
(ii) TYPE DE MOLECULE : ADNc(ii) TYPE OF MOLECULE: cDNA
( i ii ) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEU R DE LA MOLECULE : (A) TYPE DE CELLULE : bactérie(i ii) CHARACTERISTICS OF THE MOLECULAR CARRIER CELL CLONE: (A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT : 2.1 16(B) NAME OF THE cDNA CLONE IN THE APPLICANT: 2.1 16
(C) ORIGINE : Max Plank Institute for Molecular Genetics,(C) ORIGIN: Max Plank Institute for Molecular Genetics,
Laboratory of Dr Hans Lehrach, Berlin, AllemagneLaboratory of Dr Hans Lehrach, Berlin, Germany
(D) NOM DU CLONE DANS LA BANQUE D'ORIGINE :ICRFp507E07266(D) NAME OF THE CLONE IN THE BANK OF ORIGIN: ICRFp507E07266
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
GTACTGAGGG CTTTTTAGAT TC 22 (2) INFORMATIONS POUR LA SEQ ID NO 3 :GTACTGAGGG CTTTTTAGAT TC 22 (2) INFORMATION FOR SEQ ID NO 3:
(i) CARACTERISTIQUES DE LA SEQUENCE:(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LONGUEUR : 18 nucléotides(A) LENGTH: 18 nucleotides
(B) TYPE : nucléotidc(B) TYPE: nucleotide
(C) NOMBRE DE BRIN : simple(C) NUMBER OF STRANDS: single
(D) CONFIG URATION : linéaire(D) CONFIGURATION: linear
(ii) TYPE DE MOLECULE : ADNc(ii) TYPE OF MOLECULE: cDNA
(iii) CARACTERISTIQUES DU CLONE CELLU LAIRE PORTEUR DE LA MOLECULE :(iii) CHARACTERISTICS OF THE MOLECULAR CARRYING CLONE CELL:
(A) TYPE DE CELLULE : bactérie(A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT : 2.1 19 (C) ORIGINE : Max Plank Institute for Molecular Genetics,(B) NAME OF THE cDNA CLONE IN THE APPLICANT: 2.1 19 (C) ORIGIN: Max Plank Institute for Molecular Genetics,
Laboratory of Dr Hans Lehrach, Berlin, Allemagne (D) NOM DU CLONE DANS LA BANQUE D'ORIGINE :ICRFp507J 10268Laboratory of Dr Hans Lehrach, Berlin, Germany (D) NAME OF CLONE IN BANK OF ORIGIN: ICRFp507J 10268
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
TCATGCAGCA GAAAACAG 18TCATGCAGCA GAAAACAG 18
(2) INFORMATIONS POUR LA SEQID NO 4 :(2) INFORMATION FOR SEQID NO 4:
(i) CARACTERISTIQUES DE LA SEQUENCE:(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LONGUEUR : 18 nucléotides(A) LENGTH: 18 nucleotides
(B) TYPE : nucléotidc(B) TYPE: nucleotide
(C) NOMBRE DE BRIN : simple(C) NUMBER OF STRANDS: single
(D) CONFIGURATION : linéaire(D) CONFIGURATION: linear
(ii) TYPE DE MOLECULE : ADNc(ii) TYPE OF MOLECULE: cDNA
(iii) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEUR DE LA MOLECULE : (A) TYPE DE CELLULE : bactérie(iii) CHARACTERISTICS OF THE MOLECULE-CARRYING CELL CLONE: (A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT :(B) NAME OF THE cDNA CLONE IN THE APPLICANT:
(C) ORIGINE : Max Plank Institute for Moleculai Genetics,(C) ORIGIN: Max Plank Institute for Moleculai Genetics,
Laboratory of Dr Hans Lehrach, Berlin, Allemagne (D) NOM DU CLONE DANS LA BANQUE D'ORIGINE .!CRFp507J 10268Laboratory of Dr Hans Lehrach, Berlin, Germany (D) NAME OF THE CLONE IN THE BANK OF ORIGIN.! CRFp507J 10268
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
AAAGGGGAGA CCAATTTG 18AAAGGGGAGA CCAATTTG 18
(2) INFORMATIONS POUR LA SEQID NO 5 :(2) INFORMATION FOR SEQID NO 5:
(i) CARACTERISTIQUES DE LA SEQUENCE: (A) LONGUEUR : 18 nucléotides (B) TYPE : nucléotide(i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 18 nucleotides (B) TYPE: nucleotide
(C) NOMBRE DE BRIN : simple(C) NUMBER OF STRANDS: single
(D) CONFIGURATION : linéaire(D) CONFIGURATION: linear
(ii) TYPE DE MOLECULE : ADNc(ii) TYPE OF MOLECULE: cDNA
(iii) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEU R DE LA MOLECULE :(iii) CHARACTERISTICS OF THE CARRIER CELL CLONE OF THE MOLECULE:
(A) TYPE DE CELLULE : bactérie(A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT : 2.70 (C) ORIGINE : Max Plank Institute for Molecular Genetics,(B) NAME OF THE cDNA CLONE IN THE APPLICANT: 2.70 (C) ORIGIN: Max Plank Institute for Molecular Genetics,
Laboratory of Dr Hans Lehrach, Berlin, Allemagne (D) NOM DU CLONE DANS LA BANQUE DORIGINE.CRFp507K242 1 2Laboratory of Dr Hans Lehrach, Berlin, Germany (D) NAME OF THE CLONE IN THE DORIGIN BANK.CRFp507K242 1 2
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
GCACAGTCCT CACTAAAC 18GCACAGTCCT CACTAAAC 18
(2) INFORMATIONS POUR LA SEQ ID NO 6 : (i) CARACTERISTIQUES DE LA SEQUENCE(2) INFORMATION FOR SEQ ID NO 6: (i) CHARACTERISTICS OF THE SEQUENCE
(A) LONGUEUR 19 nucléotides(A) LENGTH 19 nucleotides
(B) TYPE : nucleotide(B) TYPE: nucleotide
(C) NOMBRE DE BRIN simple (D) CONFIGURATION : linéaire(C) NUMBER of single STRANDS (D) CONFIGURATION: linear
(n) TYPE DE MOLECULE ADNc(n) TYPE OF cDNA MOLECULE
(m) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEUR DE LA MOLECULE • (m) CHARACTERISTICS OF THE MOLECULE-CARRYING CELL CLONE •
(A) TYPE DE CELLULE . bactérie(A) TYPE OF CELL. bacterium
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT 2 70(B) NAME OF THE cDNA CLONE IN THE DEPOSITOR 2 70
(C) ORIGINE Max Plank Institute for Molecular Genetics,(C) ORIGIN Max Plank Institute for Molecular Genetics,
Laboratory of Dr Hans Lehrach, Berlin, Allemagne (D) NOM DU CLONE DANS LA BANQUE D'ORlGiNLICRFp507K242 l 2Laboratory of Dr Hans Lehrach, Berlin, Germany (D) NAME OF THE CLONE IN THE BANK OF ORlGiNLICRFp507K242 l 2
(iv) DESCRIPTION DE LA SEQUENCE(iv) DESCRIPTION OF THE SEQUENCE
GGACATTGGC TTCAACTTC 19GGACATTGGC TTCAACTTC 19
(2 ) INFORMAT IONS TOUR LA SEQID NO 7(2) INFORMATION ON THE SEQID NO 7
(i) CARACTERISTIQUES DE LA SEQUENCE (A) LONGUEUR 16 nucléotides (B) TYPE nucleotide(i) CHARACTERISTICS OF THE SEQUENCE (A) LENGTH 16 nucleotides (B) TYPE nucleotide
(C) NOMBRE DE BRIN . simple(C) NUMBER OF STRANDS. simple
(D) CONFIGURATION • linéaire(D) CONFIGURATION • linear
(n) TYPE DE MOLECULE . ADNc(n) TYPE OF MOLECULE. CDNA
(ni) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEUR DE LA MOLECULE(ni) CHARACTERISTICS OF THE MOLECULE-CARRYING CELL CLONE
(A) TYPE DE CELLULE bactérie ( B) NOM DU CLONE D'ADNc CHEZ LE DEPOSAN1 2 1 (C) ORIGINE Max Plank Institute for Molecular Genetics,(A) TYPE OF BACTERIA CELL (B) NAME OF THE cDNA CLONE IN THE DEPOSAN1 2 1 (C) ORIGIN Max Plank Institute for Molecular Genetics,
Laboratory of Dr Hans Lehrach, Berlin, Allemagne (D) NOM DU CLONE DANS LA BANQUE D'ORIGINE . ICREp50710522 (iv) DESCRIPTION DE LA SEQUFNCE • Laboratory of Dr Hans Lehrach, Berlin, Germany (D) NAME OF THE CLONE IN THE BANK OF ORIGIN. ICREp50710522 (iv) DESCRIPTION OF THE SEQUFNCE •
CAGGTGCAGC GTCAAA 16CAGGTGCAGC GTCAAA 16
(2) INFORMATIONS POUR LA SEQID NO 8 :(2) INFORMATION FOR SEQID NO 8:
(i) CARACTERISTIQUES DE LA SEQUENCE(i) CHARACTERISTICS OF THE SEQUENCE
(A) LONGUEUR : 16 nucléotides(A) LENGTH: 16 nucleotides
(B) TYPE : nucleotide (C) NOMBRE DE BRIN : simple(B) TYPE: nucleotide (C) NUMBER OF STRANDS: single
(D) CONFIGURATION : linéaire(D) CONFIGURATION: linear
(ii) TYPE DE MOLECULE : ADNc(ii) TYPE OF MOLECULE: cDNA
(m) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEU R DE LA(m) CHARACTERISTICS OF THE CARRIER CELL CLONE OF THE
MOLECULEMOLECULE
(A) TYPE DE CELLULE : bactérie(A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT : 2.81(B) NAME OF THE cDNA CLONE IN THE APPLICANT: 2.81
(C) ORIGINE : Max Plank Institute for Molecular Genetics, Laboratory of Dr Hans Lehrach, Berlin, Allemagne(C) ORIGIN: Max Plank Institute for Molecular Genetics, Laboratory of Dr Hans Lehrach, Berlin, Germany
(D) NOM DU CLONE DANS LA BANQUE D'ORIGINE :!CRFp507!05222(D) NAME OF THE CLONE IN THE BANK OF ORIGIN:! CRFp507! 05222
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
GGAGGAGGTG TCACAG 16GGAGGAGGTG TCACAG 16
(2) INFORMATIONS POUR LA SEQID NO 9 :(2) INFORMATION FOR SEQID NO 9:
(i) CARACTERISTIQUES DE LA SEQUENCE. (A) LONGUEUR : 19 nucléotides(i) CHARACTERISTICS OF THE SEQUENCE. (A) LENGTH: 19 nucleotides
(B) TYPE : nucleotide(B) TYPE: nucleotide
(C) NOMBRE DE BRIN : simple(C) NUMBER OF STRANDS: single
(D) CONFIGURATION : linéaire(D) CONFIGURATION: linear
(ii) TYPE DE MOLECULE : ADNc (iii ) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEU R DE LA MOLECULE :(ii) TYPE OF MOLECULE: cDNA (iii) CHARACTERISTICS OF THE CARRIER CELL CLONE OF THE MOLECULE:
(A) TYPE DE CELLULE : bactérie(A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT : i.S(B) NAME OF THE cDNA CLONE IN THE APPLICANT: i.S
(C) ORIGINE : Réseau I.M.A.G.E., Lawrence Livermore National(C) ORIGIN: I.M.A.G.E. Network, Lawrence Livermore National
Laboratories, Livermore, CA, USA.Laboratories, Livermore, CA, USA.
(D) NOM DU CLONE DANS LA BANQUE D'ORIGINE : 30262(D) NAME OF CLONE IN BANK OF ORIGIN: 30262
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
GATAAAAGGA AGGGAAAAG 19GATAAAAGGA AGGGAAAAG 19
(2) INFORMATIONS POUR LA SEQID NO 10:(2) INFORMATION FOR SEQID NO 10:
(i) CARACTERISTIQUES DE LA SEQUENCE:(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LONGUEUR : 17 nucléotides(A) LENGTH: 17 nucleotides
( B) TYPE : nucleotide(B) TYPE: nucleotide
(C) NOMBRE DE BRIN : simple(C) NUMBER OF STRANDS: single
(D) CONFIGURATION : linéaire(D) CONFIGURATION: linear
(ii) TYPE DE MOLECULE : ADNc(ii) TYPE OF MOLECULE: cDNA
(iii ) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEU R DE LA MOLECULE : (A) TYPE DE CELLULE : bactérie(iii) CHARACTERISTICS OF THE MOLECULAR CARRIER CELL CLONE: (A) CELL TYPE: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT : i.8(B) NAME OF THE cDNA CLONE IN THE APPLICANT: i.8
(C) ORIGINE : Réseau I.M.A.G.E., Lawrence Livermore National(C) ORIGIN: I.M.A.G.E. Network, Lawrence Livermore National
Laboratories, Livermore, CA, USA.Laboratories, Livermore, CA, USA.
(D) NOM DU CLONE DANS LA BANQUE D'ORIGINE : 30262(D) NAME OF CLONE IN BANK OF ORIGIN: 30262
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
GCAACACTCA GAAATGG 17 (2) INFORMATIONS POUR LA SEQ ID NO 1 1 :GCAACACTCA GAAATGG 17 (2) INFORMATION FOR SEQ ID NO 1 1:
(i) CARACTERISTIQUES DE LA SEQUENCE:(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LONGUEUR : 19 nucléotides(A) LENGTH: 19 nucleotides
(B) TYPE : nucléotidc(B) TYPE: nucleotide
(C) NOMBRE DE BRIN : simple(C) NUMBER OF STRANDS: single
(D) CONFIGURATION : linéaire(D) CONFIGURATION: linear
(ii) TYPE DE MOLECULE : ADNc(ii) TYPE OF MOLECULE: cDNA
(iii) CARACTERISTIQUES DU CLONE CELLULAI RE PORTEU R DE LA MOLECULE :(iii) CHARACTERISTICS OF THE CELLULAI CLONE REPORTED FROM THE MOLECULE:
(A) TYPE DE CELLULE : bactérie(A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT : i. 180 (C) ORIGINE : Réseau I.M.A.G.E., Lawrence Livermore National(B) NAME OF THE cDNA CLONE IN THE APPLICANT: i. 180 (C) ORIGIN: I.M.A.G.E. Network, Lawrence Livermore National
Laboratories, Ljvermore, CA, USA. (D) NOM DU CLONE DANS LA BANQUE D'ORIGINE : 153781 ou 162267Laboratories, Ljvermore, CA, USA. (D) NAME OF THE CLONE IN THE BANK OF ORIGIN: 153781 or 162267
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
AAGTCAGAGT TACTCTTGC 19AAGTCAGAGT TACTCTTGC 19
(2) INFORMATIONS POUR LA SEQ ID NO 1 2 :(2) INFORMATION FOR SEQ ID NO 1 2:
(i) CARACTERISTIQUES DE LA SEQUENCE:(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LONGUEUR : 17 nucléotides(A) LENGTH: 17 nucleotides
(B) TYPE : nucleotide(B) TYPE: nucleotide
(C) NOMBRE DE BRIN : simple (D) CONFIGURATION : linéaire(C) NUMBER OF STRANDS: simple (D) CONFIGURATION: linear
(ii) TYPE DE MOLECULE : ADNc (ni) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEUR DE LA MOLECULE(ii) TYPE OF MOLECULE: cDNA (ni) CHARACTERISTICS OF THE MOLECULE-CARRYING CELL CLONE
(A) TYPE DE CELLULE : bactérie(A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT i 180 (C) ORIGINE : Reseau I M A.G.E , I-aw rence Livermor e National(B) NAME OF THE cDNA CLONE IN THE APPLICANT i 180 (C) ORIGIN: Reseau I M A.G.E, I-aw rence Livermor e National
Laboratories, Livermore, CA, USA. (D) NOM DU CLONE DANS LA BANQUE D'ORIGINE 153781 ou 162267Laboratories, Livermore, CA, USA. (D) NAME OF THE CLONE IN THE BANK OF ORIGIN 153781 or 162267
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
GAGTGAAGTT CAGGAGG 17GAGTGAAGTT CAGGAGG 17
(2) INFORMATIONS POUR LA SEQID NO 13 :(2) INFORMATION FOR SEQID NO 13:
(i) CARACTERISTIQUES DE LA SEQUENCE(i) CHARACTERISTICS OF THE SEQUENCE
(A) LONGUEUR : 19 nucléotides(A) LENGTH: 19 nucleotides
(B) TYPE . nucleotide(B) TYPE. nucleotide
(C) NOMBRE DE BRIN : simple (D) CONFIGURATION : linéaire(C) NUMBER OF STRANDS: simple (D) CONFIGURATION: linear
(u) TYPE DE MOLECULE ADNc(u) TYPE OF cDNA MOLECULE
( m) CARACTERISTIQUES DU CLONE CELLULAI RE PORTEU R DE L\ MOLECULE .(m) CHARACTERISTICS OF THE CELLULAI CLONE RE CARRIER OF THE MOLECULE.
(A) TYPE DE CELLULE : bactérie(A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT . 1.181(B) NAME OF THE cDNA CLONE IN THE APPLICANT. 1.181
(C) ORIGINE : Réseau I. M. A.G.E., Lawrence Livermore National(C) ORIGIN: Network I. M. A.G.E., Lawrence Livermore National
Laboratories, Livermore, CA, USA. (D) NOM DU CLONE DANS LA BANQUE D'ORIGINE 1 14128Laboratories, Livermore, CA, USA. (D) NAME OF THE CLONE IN THE BANK OF ORIGIN 1 14128
(iv) DESCRIPTION DE LA SEQUENCE(iv) DESCRIPTION OF THE SEQUENCE
GGACAAAGCT ACATGTCAG 19 19GGACAAAGCT ACATGTCAG 19 19
(2) INFORMATIONS POUR LA SEQID NO 14 :(2) INFORMATION FOR SEQID NO 14:
(i) CARACTERISTIQUES DE LA SEQUENCE (A) LONGUEUR : 16 nucléotides (B) TYPE : nucleotide(i) CHARACTERISTICS OF THE SEQUENCE (A) LENGTH: 16 nucleotides (B) TYPE: nucleotide
(C) NOMBRE DE BRIN : simple(C) NUMBER OF STRANDS: single
(D) CONFIGURATION : linéaire(D) CONFIGURATION: linear
(n) TYPE DE MOLECULE : ADNc(n) TYPE OF MOLECULE: cDNA
(ni) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEUR DE LA MOLECULE :(ni) CHARACTERISTICS OF THE MOLECULE-CARRYING CELL CLONE:
(A) TYPE DE CELLULE : bactérie(A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT : 1.181 (C) ORIGINE : Réseau LM.A.G.E , Lawrence Livermore National(B) NAME OF THE cDNA CLONE IN THE APPLICANT: 1.181 (C) ORIGIN: LM.A.G.E Network, Lawrence Livermore National
Laboratories, Livermore, CA, USA. (D) NOM DU CLONE DANS LA BANQUE D'ORIGINE . 1 14128Laboratories, Livermore, CA, USA. (D) NAME OF THE CLONE IN THE BANK OF ORIGIN. 1 14128
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
GGTGAGTGTC CTTCTG 16GGTGAGTGTC CTTCTG 16
(2) INFORMATIONS POUR LA SEQID NO 15 .(2) INFORMATION FOR SEQID NO 15.
(i) CARACTERISTIQUES DE LA SEQUENCE(i) CHARACTERISTICS OF THE SEQUENCE
(A) LONGUEUR : 15 nucléotides(A) LENGTH: 15 nucleotides
(B) TYPE : nucleotide(B) TYPE: nucleotide
(C) NOMBRE DE BRIN : simple(C) NUMBER OF STRANDS: single
(D) CONFIGURATION : linéaire(D) CONFIGURATION: linear
(ii) TYPE DE MOLECULE : ADNc(ii) TYPE OF MOLECULE: cDNA
(iii ) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEUR DE LA MOLECULE : (A) TYPE DE CELLULE : bactérie(iii) CHARACTERISTICS OF THE MOLECULE-CARRYING CELL CLONE: (A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT : i 182 (C) ORIGINE : Réseau LM.A.G.E., Lau rence Livermore National(B) NAME OF THE cDNA CLONE IN THE APPLICANT: i 182 (C) ORIGIN: LM.AGE Network, Lau rence Livermore National
Laboratories, Livermore, CA, USA.Laboratories, Livermore, CA, USA.
(D) NOM DU CLONE DANS LA BANQUE D'ORIGINE : 67444(D) NAME OF CLONE IN BANK OF ORIGIN: 67444
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
GGGCTAAGGG GAAAG 15GGGCTAAGGG GAAAG 15
(2) INFORMATIONS POUR LA SEQ ID NO 16 :(2) INFORMATION FOR SEQ ID NO 16:
(i) CARACTERISTIQUES DE LA SEQUENCE:(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LONGUEUR : 15 nucléotides(A) LENGTH: 15 nucleotides
(B) TYPE : nucleotide(B) TYPE: nucleotide
(C) NOMBRE DE BRIN : simple (D) CONFIGURATION : linéaire(C) NUMBER OF STRANDS: simple (D) CONFIGURATION: linear
(ii) TYPE DE MOLECULE : ADNc(ii) TYPE OF MOLECULE: cDNA
(iii ) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEU R DE LA MOLECULE :(iii) CHARACTERISTICS OF THE CARRIER CELL CLONE OF THE MOLECULE:
(A) TYPE DE CELLULE : bactérie(A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT : 1.182(B) NAME OF THE cDNA CLONE IN THE APPLICANT: 1.182
(C) ORIGINE : Réseau LM.A.G. E., Lawrence Livermore National(C) ORIGIN: LM.A.G. network E., Lawrence Livermore National
Laboratories, Livermore, CA, USA. (D) NOM DU CLONE DANS LA BANQUE D'ORIGINE : 67444Laboratories, Livermore, CA, USA. (D) NAME OF CLONE IN BANK OF ORIGIN: 67444
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
CTTGGTGGGC AAGTG 15CTTGGTGGGC AAGTG 15
(2) INFORMATIONS POUR LA SEQ ID NO 17 :(2) INFORMATION FOR SEQ ID NO 17:
(i) CARACTERISTIQUES DE LA SEQUENCE: (A) LONGUEUR : 18 nucléotides (B) TYPE : nucleotide(i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 18 nucleotides (B) TYPE: nucleotide
(C) NOMBRE DE BRIN : simple(C) NUMBER OF STRANDS: single
(D) CONFIGURATION : linéaire (ii) TYPE DE MOLECULE : ADNc(D) CONFIGURATION: linear (ii) TYPE OF MOLECULE: cDNA
(iii ) CARACTERISTIQUES DU CLONE CELLULAIRE PORTEUR DE LA MOLECULE : (A) TYPE DE CELLULE : bactérie(iii) CHARACTERISTICS OF THE MOLECULE-CARRYING CELL CLONE: (A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT : 2.46(B) NAME OF THE cDNA CLONE IN THE APPLICANT: 2.46
(C) ORIGINE : Max Plank Institute for molecular Genetics,(C) ORIGIN: Max Plank Institute for molecular Genetics,
Laboratory of Dr Hans Lehrach, Berlin, Allemagne.Laboratory of Dr Hans Lehrach, Berlin, Germany.
(D) NOM DU CLONE DANS LA BANQUE D'ORIGINE :ICRFp507E06174(D) NAME OF THE CLONE IN THE BANK OF ORIGIN: ICRFp507E06174
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
TTTTTACTCG CGGCGGTG 18TTTTTACTCG CGGCGGTG 18
(2) INFORMATIONS POUR LA SEQ ID NO 1 8 :(2) INFORMATION FOR SEQ ID NO 1 8:
(i) CARACTERISTIQUES DE LA SEQUENCE:(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LONGUEUR : 25 nucléotides(A) LENGTH: 25 nucleotides
(B) TYPE : nucleotide (C) NOMBRE DE BRIN : simple(B) TYPE: nucleotide (C) NUMBER OF STRANDS: single
( D) CONFIGURATION : linéaire(D) CONFIGURATION: linear
(ii) TYPE DE MOLECULE : ADNc(ii) TYPE OF MOLECULE: cDNA
( iii ) CARACTERISTIQUES DU CLONE CELLULAIR E PORTEU R DE LA(iii) CHARACTERISTICS OF THE CELLULAR CLONE AND CARRIER OF THE
MOLECULE :MOLECULE :
(A) TYPE DE CELLULE : bactérie(A) TYPE OF CELL: bacteria
(B) NOM DU CLONE D'ADNc CHEZ LE DEPOSANT : 2.46(B) NAME OF THE cDNA CLONE IN THE APPLICANT: 2.46
(C) ORIGINE : Max Plank Institute for molecular Genetics, Laboratory of Dr Hans Lehrach, Berlin, Allemagne.(C) ORIGIN: Max Plank Institute for molecular Genetics, Laboratory of Dr Hans Lehrach, Berlin, Germany.
(D) NOM DU CLONE DANS LA BANQUE D'ORIGINE : lCRfρ507E06 l 74(D) NAME OF THE CLONE IN THE BANK OF ORIGIN: lCRfρ507E06 l 74
(iv) DESCRIPTION DE LA SEQUENCE :(iv) DESCRIPTION OF THE SEQUENCE:
CAGGATAATC AAGAATGAAG TTAAG 25 ~)1CAGGATAATC AAGAATGAAG TTAAG 25 ~) 1
(2) INFORMATIONS POUR LA SEQ ID NO: 19(2) INFORMATION FOR SEQ ID NO: 19
i) CARACTERISTIQUES DE LA SEQUENCEi) CHARACTERISTICS OF THE SEQUENCE
(A) LONGUEUR: 2227 nucléotides(A) LENGTH: 2227 nucleotides
(B) TYPE: nucleotide(B) TYPE: nucleotide
(C) NOMBRE DE BRINS, simple(C) NUMBER OF STRANDS, single
(D) CONFIGURATION- linéaire(D) CONFIGURATION- linear
(ii) TYPE DE MOLECULE. ADNc(ii) TYPE OF MOLECULE. CDNA
(îx) CARACTERISTIQUE(îx) CHARACTERISTIC
(A) NOM/CLE: 2.116(A) NAME / KEY: 2.116
(B) EMPLACEMENTxhromosome 3pl4(B) LOCATIONxhromosome 3pl4
(xi) DESCRIPTION DE LA SEQUENCE: SEQ ID NO.19 gccggaagtggggtg gaagccccggtgctggtgcggcgggggactgcggggccagccec aggtagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag cagcagcaatgt tcacttct cagaaagcctccggaaεctaaaaagccctcagcaccag agacagaagcagaεgga ccgεcc εεεaggagaεacaacagatgagcaaagaa gacag caagaggcaaaac cggacatagaggccaaccaacctεεggagaccaacaaagaaaaεε catccagtgtgac g a cagaccctgagacggaaaataaggcaggccagactccggaga acagcεcaεcaa ggccgagcεcctgaacga gεgccgε cacccεggccccgcaεg gc εggcagcacagggcacca cacεgacc cccgaccac εacεcccc a gatggcagcg aaaaccεatcacggεttεggεatgattccaccc εgaaaaεεcagεgc cεgεga tcaε aaccεεεaεg cεgtεεgcaccεεaacagcεεεaaaaεaεgcεcgccεa ε a cεaac ctgεεεgaεgcεctcεgccg εεcacεgεtεaaggtccεcagcaaggaεcacaaagcaaa gaaaa agcatεa g εcactacεcεa ttεaagaaaaaggεaca gεa acaaaεε gaactcaag tccac cccttcccccaεacaa aaata acaaac aggc atgaaggc t aggaaaggac cga ccεεcagaεggtc c caaaata aacaccεcaaaε acc εtagaagaacεgεgaaaaagaaεεgεggcaεεεεεcagεcacεacagcεccgaagεcεga gcaagaagεgggεgtgaagtc ccεc cεggε εgεaggaagεεgaaε agεgεεa cc εgcaεεεtt cεεccacagtgε aεgaatgaaεεcagaaaaaaag gccagtcagcε taatttc tcagaεgcat gaεgεggaatεεaaaacεcgεcc aaacagca gc ag tgcεgatacaaggatgcεagacctgctctgcgεgctc εεctggagεggcccaεεεcggε εctcεgaaacccacggcagccctttccaεcgεgaataaεcgt gεgεεcccaccεεεgtc ccctgccεtεtεgctactεcagεgcgcεctcεgaccagcε ccaaagaacεεtcccεgc t ctgcctcggttgccac gcεcεcct accacaεacgεεcccagεεεaεgaagaga c cacatt cctεεcaacccc ctgccεccCgaagaaaaacatcεcatgatga aca a a ttgcεgaεaacaccct atctagaaatεcgcεggccacaatacagaεggaaaεg c ac εgcεggaaaaacεgaaa caacccat ccaaεεagag aεaggcagaacacc agaεa gact εtagεtcεcgaaεaεccaεtaccεacεεεaaεgaaaacagaacεgccaεεggεca ataaacεgtaaagggaagaggtaaaεtgtgaεagagaaεt cεatgεcaεgggaaa εg aaaccaca aεε ga εaccagcaaεaεga εa aac c gεgccaagεεεεaag εaεatttεctcacaaagaεagagtgccatagtgaaacCaaacacεgεgcaεaaaggεaca εgaat acεccaguεt aaagεa atgcat g aa aaatgεggcaεgg a aεacaaacgcεacgεcact aaaagεcagaggaacaεtεcεaεεgacaaaaaεacgcεεc acεcacaεataaεgtcaccaεacggεgtcaatgatεaaaεtaga cεεcaca ag c acaaagcaεcagεctaggaaa atgacεta εactgaεgcaaatg gaacaεε gεagε agttttgεaaaagaacatcctttεcaaatatccacgtcaacgtacccccgaaattaaacj caagcacaεagεcagεεεgεctaaεtεtgεgεgaaaεεεεgεcgaaaaεaccεaaacaε;- ccatcεaεatεεgεgccεaccaεgεεεataaatgεtccaεaagεaccεεccaεgεεgtεc taεaaaaaaεg ataεεtaaaεaaatgtgaaεεaaaaεaaaaεεεεεgaεεaεεεεccg atccccg REFERENCES(Xi) SEQUENCE DESCRIPTION: SEQ ID NO.19 gccggaagtggggtg gaagccccggtgctggtgcggcgggggactgcggggccagccec aggtagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag cagcagcaatgt tcacttct cagaaagcctccggaaεctaaaaagccctcagcaccag agacagaagcagaεgga ccgεcc εεεaggagaεacaacagatgagcaaagaa gacag caagaggcaaaac cggacatagaggccaaccaacctεεggagaccaacaaagaaaaεε catccagtgtgac ga cagaccctgagacggaaaataaggcaggccagactccggaga acagcεcaεcaa ggccgagcεcctgaacga gεgccgε cacccεggccccgcaεg gc εggcagcacagggcacca cacεgacc cccgaccac εacεcccc has gatggcagcg aaaaccεatcacggεttεggεatgattccaccc εgaaaaεεcagεgc cεgεga tcaε aaccεεεaεg cεgtεεgcaccεεaacagcεεεaaaaεaεgcεcgccεa ε has cεaac ctgεεεgaεgcεctcεgccg εεcacεgεtεaaggtccεcagcaaggaεcacaaagcaaa gaaaa agcatεa g εcactacεcεa ttεaagaaaaaggεaca gεa acaaaεε gaactcaag tccac cccttcccccaεacaa aaata acaaac aggc atgaaggc t aggaaaggac cga ccεεcagaεggtcac caaaaaageac ggcaεεεεεcagεcacεacagcεccgaagεcεga gcaagaagεgggεgtgaagtc ccεc cεggε εgεaggaagεεgaaε agεgεεa cc εgcaεεεtt cεεccacagtgε aεgaatgaaεεcagaaaaaaag gccagtcagcε taatttc tcagaεgcat gaεgεggaatεεaaaacεcgεcc aaacagca gc ag tgcεgatacaaggatgcεagacctgctctgcgεgctc εεctggagεggcccaεεεcggε εctcεgaaacccacggcagccctttccaεcgεgaataaεcgt gεgεεcccaccεεεgtc ccctgccεtεtεgctactεcagεgcgcεctcεgaccagcε ccaaagaacεεtcccεgc t ctgcctcggttgccac gcεcεcct accacaεacgεεcccagεεεaεgaagaga c cacatt cctεεcaacccc ctgccεccCgaagaaaaacatcεcatgatga aca aa ttgcεgaεaacaccct atctagaaatεcgcεggccacaatacagaεggaaaεg c ac εgcεggaaaaacεgaaa caacccat ccaaεεagag aεaggcagaacacc agaεa CTAG εtagεtcεcgaaεaεccaεtaccεacεεεaaεgaaaacagaacεgccaεεggεca ataaacεgtaaagggaagaggtaaaεtgtgaεagagaaεt cεatgεcaεgggaaa εg aaaccaca aεε ga εaccagcaaεaεga εa aac c gεgccaagεεεεaag εaεatttεctcacaaagaεagagtgccatagtgaaacCaaacacεgεgcaεa aaggεaca εgaat acεccaguεt aaagεa atgcat g aa aaatgεggcaεgg has aεacaaacgcεacgεcact aaaagεcagaggaacaεtεcεaεεgacaaaaaεacgcεεc acεcacaεataaεgtcaccaεacggεgtcaatgatεaaaεtaga cεεcaca ag c acaaagcaεcagεctaggaaa atgacεta εactgaεgcaaatg gaacaεε gεagε agttttgεaaaagaacatcctttεcaaatatccacgtcaacgtacccccgaaattaaacj caagcacaεagεcagεεεgεctaaεtεtgεgεgaaaεεεεgεcgaaaaεaccεaaacaε - ccatcεaεatεεgεgccεaccaεgεεεataaatgεtccaεaagεaccεεccaεgεεgtεc taεaaaaaaεg ataεεtaaaεaaatgtgaaεεaaaaεaaaaεεεεεgaεεaεεεεccg atccccg REFERENCES
1. Whilhem, P.J. Dynamic mutations hit double figures. Nature Genêt. 8, 213-215 (1994).1. Whilhem, P.J. Dynamic mutations hit double figures. Nature Broom. 8, 213-215 (1994).
2. Trottier, Y. et al. Cellular localization of the Huniington's disease protein and discrimination oî the normal and mutant form. Nature Genêt. 10, 104-110 ( 1995).2. Trottier, Y. et al. Cellular localization of the Huniington's disease protein and discrimination oî the normal and mutant form. Nature Broom. 10, 104-110 (1995).
3. Servadio, A. et al. Expression analysis of the ataxin- 1 protein in tissues from normal and spinocerebellar ataxia type 1 individuals.3. Servadio, A. et al. Expression analysis of the ataxin- 1 protein in tissues from normal and spinocerebellar ataxia type 1 individuals.
Narure Gêner. 10, 94-98 ( 1995).Embarrassing. 10, 94-98 (1995).
4. Yazawa, I. et al. Abnormal gène product identified in hereditary dentato-rubralpallidoluysian atrophy (DRPLA) brain. Nature Genêt. 10, 99-103 (1995). 5. Meier-Ewert, S., Maier, E, Ahmadi, A., Curtis, J. and Lebrach, H. An4. Yazawa, I. et al. Abnormal gene product identified in hereditary dentato-rubralpallidoluysian atrophy (DRPLA) brain. Nature Broom. 10, 99-103 (1995). 5. Meier-Ewert, S., Maier, E, Ahmadi, A., Curtis, J. and Lebrach, H. An
Automated approach to generating e pressed séquence catalogues. Nature 361, 375 (1993).Automated approach to generating e pressed sequence catalogs. Nature 361, 375 (1993).
6. Soares, M.B., Bonaldo, M.F., Jelene, P., Su, L, Lawton, L & Efstratiadis, A. Construction and characterization of a normalized cDNA library. Proc. Natl. Acad. Sci. USA. 91 , 9228-9232 ( 1994).6. Soares, M.B., Bonaldo, M.F., Jelene, P., Su, L, Lawton, L & Efstratiadis, A. Construction and characterization of a normalized cDNA library. Proc. Natl. Acad. Sci. USA. 91, 9228-9232 (1994).
7. Haad, D., Perry, M.J. and Haynes, L. Cellular transglutaminases in neural development. Int. J. Devl Neuroscience 1 1 , 709-720 ( 1993).7. Haad, D., Perry, M.J. and Haynes, L. Cellular transglutaminases in neural development. Int. J. Devl Neuroscience 11, 709-720 (1993).
8. Stott, K., Blackburn, J.M., Butler, P.J.G. & Perutz, M. Incorporation of glutamine repcats makes protein oligomerize. Implications for neuro- degenerative diseases. Proc. Natl. Acad. Sci. USA, 92, 6509-6513 ( 1995). 8. Stott, K., Blackburn, J.M., Butler, P.J.G. & Perutz, M. Incorporation of glutamine repcats makes protein oligomerize. Implications for neuro-degenerative diseases. Proc. Natl. Acad. Sci. USA, 92, 6509-6513 (1995).
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9529061A JP2000505293A (en) | 1996-02-15 | 1997-02-17 | Diagnosis of trinucleotide repeat disease and genes involved in this disease |
| EP97905219A EP0894144A2 (en) | 1996-02-15 | 1997-02-17 | Diagnosing trinucleotide repeat diseases and genes involved therein |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9601864A FR2745007B1 (en) | 1996-02-15 | 1996-02-15 | DIAGNOSIS OF TRINUCLEOTIDE REPEATED DISEASES AND GENES INVOLVED IN SUCH DISEASES |
| FR96/01864 | 1996-02-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997030178A2 true WO1997030178A2 (en) | 1997-08-21 |
| WO1997030178A3 WO1997030178A3 (en) | 1997-10-16 |
Family
ID=9489220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FR1997/000297 WO1997030178A2 (en) | 1996-02-15 | 1997-02-17 | Diagnosing trinucleotide repeat diseases and genes involved therein |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0894144A2 (en) |
| JP (1) | JP2000505293A (en) |
| CA (1) | CA2246362A1 (en) |
| FR (1) | FR2745007B1 (en) |
| WO (1) | WO1997030178A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998056950A1 (en) * | 1997-06-11 | 1998-12-17 | Fondation Jean Dausset-Ceph | Dna sequences rich in triplet repeat useful in the diagnosis of trinucleotide repeat disorders |
| WO2003014396A1 (en) * | 2001-08-06 | 2003-02-20 | Biomedlab Corporation | Diagnosis method of multiplication disease of trinucleotide repeated sequence and a diagnosis kit |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9202485D0 (en) * | 1992-02-06 | 1992-03-25 | Univ Wales Medicine | Dna sequences and materials and methods for the diagnosis of myotonic dystrophy |
| DE69313829D1 (en) * | 1992-02-18 | 1997-10-16 | Univ Ottawa | Myotonic distrophy |
| US5834183A (en) * | 1993-06-29 | 1998-11-10 | Regents Of The University Of Minnesota | Gene sequence for spinocerebellar ataxia type 1 and method for diagnosis |
-
1996
- 1996-02-15 FR FR9601864A patent/FR2745007B1/en not_active Expired - Fee Related
-
1997
- 1997-02-17 WO PCT/FR1997/000297 patent/WO1997030178A2/en not_active Application Discontinuation
- 1997-02-17 JP JP9529061A patent/JP2000505293A/en active Pending
- 1997-02-17 EP EP97905219A patent/EP0894144A2/en not_active Withdrawn
- 1997-02-17 CA CA002246362A patent/CA2246362A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998056950A1 (en) * | 1997-06-11 | 1998-12-17 | Fondation Jean Dausset-Ceph | Dna sequences rich in triplet repeat useful in the diagnosis of trinucleotide repeat disorders |
| WO2003014396A1 (en) * | 2001-08-06 | 2003-02-20 | Biomedlab Corporation | Diagnosis method of multiplication disease of trinucleotide repeated sequence and a diagnosis kit |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2745007A1 (en) | 1997-08-22 |
| JP2000505293A (en) | 2000-05-09 |
| WO1997030178A3 (en) | 1997-10-16 |
| FR2745007B1 (en) | 1998-05-07 |
| CA2246362A1 (en) | 1997-08-21 |
| EP0894144A2 (en) | 1999-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wallace et al. | Statistical colocalization of monocyte gene expression and genetic risk variants for type 1 diabetes | |
| EP1601798B1 (en) | Probe biochips and methods for use thereof | |
| Gismondi et al. | Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas | |
| Granados et al. | Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides | |
| Lanktree et al. | Evolving role of genetic testing for the clinical management of autosomal dominant polycystic kidney disease | |
| Zheng et al. | The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients | |
| Sykiotis et al. | Oligogenic basis of isolated gonadotropin-releasing hormone deficiency | |
| Bonnefond et al. | Highly sensitive diagnosis of 43 monogenic forms of diabetes or obesity through one-step PCR-based enrichment in combination with next-generation sequencing | |
| EP1382693B1 (en) | Methods and compositions for the detection of pathologic events | |
| Demosthenous et al. | X‐linked Alport syndrome in Hellenic families: Phenotypic heterogeneity and mutations near interruptions of the collagen domain in COL4A5 | |
| Jung et al. | Mutations causing Lopes-Maciel-Rodan syndrome are huntingtin hypomorphs | |
| Kitano et al. | Human-specific amino acid changes found in 103 protein-coding genes | |
| Traherne et al. | Association of the truncating splice site mutation in BTNL2 with multiple sclerosis is secondary to HLA-DRB1* 15 | |
| Krüger et al. | Genetic polymorphisms and the fate of the transplanted organ | |
| Wang et al. | The Gly460Trp Variant Of α-Adducin Is Not Associated With Hypertension In White Anglo− Australians | |
| Song et al. | Whole exome sequencing in patients with phenotypically associated familial intracranial aneurysm | |
| Pezzolesi et al. | Insights to the genetics of diabetic nephropathy through a genome-wide association study of the GoKinD collection | |
| EP1179091B2 (en) | Method for analysing a patient's genetic predisposition to at least a disease and amplification adapted to such a method | |
| Bodmer | The human genome sequence and the analysis of multifactorial traits | |
| EP0763136B1 (en) | Method and probes for detecting markers bound to the locus of child spinal muscular atrophies | |
| EP0894144A2 (en) | Diagnosing trinucleotide repeat diseases and genes involved therein | |
| EP1220950B1 (en) | Genetic markers of toxicity, preparation and uses thereof | |
| EP0988399A1 (en) | Dna sequences rich in triplet repeat useful in the diagnosis of trinucleotide repeat disorders | |
| Sawcer | The genetic aspects of multiple sclerosis | |
| Kransdorf et al. | Genetic and genomic approaches to the detection of heart transplant rejection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase |
Ref document number: 2246362 Country of ref document: CA Ref country code: CA Ref document number: 2246362 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1997905219 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1997905219 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1997905219 Country of ref document: EP |